SUPEROXIDE DISMUTASE ACTIVITY AND SERUM LIPID PROFILE IN HEMODIALYSIS PATIENTS
Hemodialysis (HD) is the most frequently used form of renal replacement therapy for many patients with end-stage renal disease (ESRD). One of the leading causes of morbidity and mortality in HD patients is cardiovascular disease (CVD). In 1998, the National Kidney Foundation reported that, at er stratifying for age, race, and gender, mortality from CVD in HD patients was 10-30 times greater than in the general population (1). Despite the neutral ef ect, HD is associated with a number of biochemical abnormalities including dyslipidemia and oxidative stress. Renal dyslipidemia is caused by certain dialysis-related parameters, which may signii cantly af ect lipoprotein metabolism and modify the composition of plasma lipoproteins. It appears that a reduced catabolism and clearance of Apo B-containing lipoproteins of hepatic and intestinal origin constitutes the main abnormality. SUPEROXIDE DISMUTASE ACTIVITY AND SERUM LIPID PROFILE IN HEMODIALYSIS PATIENTS